海南医科大学学报

目的:探讨齐拉西酮与氯氮平治疗女性精神分裂症的疗效及安全性比较。方法:将80例女性精神分裂症患者随机分为研究组和对照组,每组40例,分别给予齐拉西酮与氯氮平治疗,观察8周,以阳性和阴性症状量表(PANSS)和副反应量表(TESS)评定临床疗效和药物不良反应,统计学处理采用2χ和t检验。结果:治疗后,两组PANSS总分和各因子分均较治疗前下降(均P<0.05),但组间差异无统计学意义(均P>0.05);研究组不良反应发生率较对照组显著为低(P<0.05)。结论:齐拉西酮治疗女性精神分裂症与氯氮平疗效相当,但不良反应少,对患者月经和体质量没有明显影响,可作为治疗女性精神分裂症的首选药物。

Objective: To explore efficacy and safety of ziprasidone and clozapine in treatment of female schizophrenia.Methods: All 80 female patients with schizophrenia diagnosed according to CCMD-3-R criteria were randomly divided into two groups treated with ziprasidone or clozapine,respectively for 8 weeks.The Positive and Negative Syndrome Scale(PANSS) and Treatment Emergent Side-effect Scale(TESS) were used to evaluate the efficacy and advers effect,respectively.Results: The clinical efficacy had no significant difference between the two groups.The scores of PANSS in two groups after treatment were significantly lower than those before.But the scores of PANSS had no significant difference between the two groups.The incidence of adverse effect in the study group was significantly lower than that in the control group.Conclusions: Ziprasidone is as effective as clozapine in treatment of female schizophrenia.But it is much safer than clozapine.